Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.48 |
| ▸ | YAP1 | P46937 | 3/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486941 | 0.88 | USP30 (0.47) | — | |
| SCHEMBL4687159 | 0.85 | ACACB (0.52) | ACACBMMP13MMP14KDM4EMCHR1 | |
| SCHEMBL4233654 | 0.84 | GPR119 (0.48) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL76105 | 0.84 | YAP1 (0.60) | YAP1PRMT5 | |
| SCHEMBL7476303 | 0.83 | SMN1; SMN2 (0.51) | ACACBSMN1; SMN2ALDH1A1 | |
| SCHEMBL7486858 | 0.81 | LIPE (0.49) | ACACBSMN1; SMN2 | |
| SCHEMBL7481961 | 0.81 | GPR119 (0.47) | SMN1; SMN2 | |
| SCHEMBL28285822 | 0.80 | ACACB (0.49) | ACACBMMP13MMP14KDM4EMCHR1 | |
| SCHEMBL2174388 | 0.80 | KMT2A (0.47) | MMP13 | |
| SCHEMBL7479678 | 0.80 | GPR119 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | ACACB 2790/4885YAP1 1101/4885MMP13 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.